Petronet LNG share price: Nomura sees this announcement as a positive development. The international brokerage kept a 'Buy' call on the stock, with a target price implying an upside potential of nearly 34%.
IndiGo share price: The shares dropped to Rs 5,405 apiece in the morning, the lowest level seen by the stock in more than five months.
Corona Remedies IPO | The company has revised its IPO size to Rs 655.37 crore, lower than the Rs 800 crore initially planned at the time of submitting draft papers in late April.
Nephrocare Health Services IPO | The company aims to raise Rs 353.4 crore by issuing fresh shares, while promoters and investors will be selling up to 1.12 crore equity shares via offer-for-sale.
The US biosimilars market is projected to balloon from about $22.6 billion in 2025 to more than $90 billion by 2034, according to industry estimates.
The rupee crossed the 90-mark against the US dollar on persistent outflows and uncertainty around the India-US trade deal
Tata Communications share price: Macquarie kept a ‘Buy’ call on the stock, with a target price of Rs 2,210 per share. This implies an upside potential of nearly 20% from the stock’s previous closing price.
Aequs IPO GMP: Aequs launched its IPO to raise around Rs 922 crore through a fresh issue of shares worth Rs 670 crore and an OFS of shares worth Rs 251.81 crore.
The company, however, cannot sell the drug in the country till March 2026, when Novo Nordisk’s secondary patent expires
Aequs IPO | The initial share sale will open for subscription on December 3 and close on December 5.
More than 60 institutional investors participated in the anchor round.
Meesho IPO: Meesho intends to use the funds for investments in cloud infrastructure, marketing and brand-building, inorganic growth through acquisitions, and other general corporate purposes.
The anchor book attracted 10 institutional investors, with domestic mutual funds accounting for 77.78 percent of the total allocation. These domestic funds invested through seven schemes across three fund houses.
Other investors including GIC, ADIA, Fidelity International, Fidelity Management & Research, Baillie Gifford, Wellington and Goldman Sachs Asset Management also bid to participate in the anchor round, a source told Moneycontrol.
That decision triggered a pushback from other large funds, the people said, asking not to be identified as the information is private. Meesho is set to open its anchor book — a portion of shares reserved for institutional investors — on Tuesday ahead of its initial public offering that launches on Wednesday
The next critical steps in the USFDA process involve a rigorous on-site evaluation: "visiting manufacturing facilities, inspecting documents, and so on".
Earlier in November, RBI Governor Sanjay Malhotra said there is scope to further reduce policy interest rates, spurring rate cut hopes. However, strong GDP numbers lowered expectations of further monetary easing.
Khorakiwala said the Mumbai-based drugmaker is already laying groundwork for commercialization, with options ranging from solo marketing to partnerships in the US.
In the mainboard segment, all three IPOs - Meesho, Aequs, and Vidya Wires - will have same schedule, opening for subscription on December 3 and closing on December 5.
Wakefit Innovations IPO | The Bengaluru-based company aims to raise Rs 377.1 crore via issue of fresh shares, while existing shareholders including promoters will be selling up to 4.67 crore equity shares via offer-for-sale.
AI may or may not fulfil its most ambitious promises, but the infrastructure powering AI is set for an unavoidable and sustained boom.
Mumbai-based K K Silk Mills is raising Rs 28.5 crore via initial share sale of 75 lakh shares, consisting entirely fresh issue component.
MV Electrosystems IPO | The initial share sale comprises of entirely fresh issue with no offer-for-sale component.
Cipla's wants to create awareness, help diagnostics, provide solutions and rehab support, COO Achin Gupta tells Moneycontrol, as the firm doubls down on its lung-care strategy
What began as a creative hack to grab attention has quickly become a gimmick. And like all gimmicks, it risks trivialising something important
